CYMS101 for multiple sclerosis
phase 1drug program · high · Fri Oct 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat refractory relapsing-remitting multiple sclerosis through immune modulation by tolerogenic fibroblasts.
Intravenous administration of 100 million tolerogenic fibroblasts in a feasibility study assessing primary safety and secondary efficacy endpoints in 5 patients with relapsing-remitting MS resistant to interferon.
Clinical study record exists for tolerogenic fibroblasts in refractory MS; company update said it was preparing to submit an IND for CYMS101 in multiple sclerosis.
The clinical trial rationale states fibroblasts demonstrated immune modulatory and therapeutic activity in the EAE model of multiple sclerosis and other autoimmune/inflammatory disease models; clinical efficacy was not yet established in the supplied material.